This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
No power calculations to determine the sample size were reported. Details of the sample selection were not reported, but all eligible patients were included. There were 30 patients in each group. The number of patients excluded from the study after the initial recruitment was not recorded.
Study design
This was a randomised controlled trial that was carried out in a single centre. Crossover was offered to patients if the assigned strategy did not produce a diagnosis. The method of randomisation and the loss to follow-up were not reported. Details of the study have been published elsewhere, (see Other Publications of Related Interest).
Analysis of effectiveness
The basis of the analysis was intention to treat. The groups were shown to be similar at baseline, although statistical tests were not used. Effectiveness was measured by the ability to give a diagnosis.
Effectiveness results
Fourteen of the 30 patients assigned to long-term monitoring were diagnosed, compared with 6 of the 30 patients assigned to conventional testing.
Those patients who were not diagnosed in their allocated group were than offered the opportunity to crossover. Of the 16 undiagnosed patients in the long-term group, 5 consented to conventional testing and one of these was diagnosed. Of the 24 undiagnosed patients in the conventional group, 21 opted for long-term monitoring and 8 of these were diagnosed.
Clinical conclusions
When patients with unexplained syncope were considered suitable candidates for long-term monitoring with an implantable loop recorder, such testing would be more likely to lead to a diagnosis than conventional testing with an external loop recorder, tilt and electrophysiologic testing. If patients were given conventional testing after long-term monitoring has failed to yield a diagnosis (as in the crossover strategy), this would lead to the maximum number of diagnoses in the shortest time.
Measure of benefits used in the economic analysis
The benefit measure, diagnoses made, was taken directly from the effectiveness measure.
Direct costs
No discounting was carried out since the costs were incurred during less than 2 years. The quantities and the costs were analysed separately. The costs included were for external loop recording, transtelephonic monitoring, Holter monitoring, echocardiography, tilt-table test, electrophysiologic testing, implanted loop recorder, implanted loop recorder removal, cardiac catheterisation, stress test, stress methoxyisobutyl isonitrile, radionuclide wall motion study, electrocardiography, electroencephalography, loop recorder follow-up, neurology consultation, cardiology consultation, family practice assessment, family practice follow-up, emergency room visit, one day in-hospital monitoring, computed tomography of the head, magnetic resonance imaging of the head, and carotid doppler. The costs were based on actual data, derived from the examination of medical records. The costs of investigations were based on the Ontario Health Insurance Programme fee schedule for technical and professional fees. Materials, labour and overhead for hospitalbased investigations were estimated from hospital sources. The price year was 2002.
The analysis used a randomised controlled trial, which was appropriate for the study question. Full details of the parent study were published elsewhere (see Other Publications of Related Interest). The authors described the characteristics of the patients in the two groups, showing them to be similar. However, they did not show that the patients were typical of patients with unexplained syncope. One of the exclusion criterions was whether or not the patient was likely to die within one year. There was no explanation for the choice of this criterion. The authors' conclusion that long-term monitoring is the best strategy to start with depends partly on the assumption that a one-year wait for a diagnosis is not too long.
Validity of estimate of measure of benefit
The measure of benefit used was obtained directly from the effectiveness analysis. Although it may be useful to ascertain the cost per diagnosis, this choice of benefit measure makes comparison with other technologies difficult. A quality of life measure may have been more useful. In addition, the one-year wait for a diagnosis may have resulted in the patient preferring the conventional method. Thus, incorporating a quality of life measure might have affected the results obtained.
Validity of estimate of costs
The authors described the costs calculated as being societal, but no indirect costs were included. Within the category of direct costs, the authors only included those costs involved in testing. They did not include the prophylactic antibiotics or any other treatment costs, although it is possible that there were none. It is unclear whether the omission of the indirect costs would have changed the results. The authors also did not include the costs incurred when screening patients to decide their eligibility for the trial. It was unclear whether these costs would normally be incurred for both types of testing, in which case their exclusion would be valid. The costs were reported separately from the quantities, which will aid generalisability to other settings. The quantities were taken from a single study. It was not possible to ascertain their validity given that no statistical or sensitivity analyses were carried out. The prices were taken from the authors' setting and from published sources. The authors did not provide clear information about the dates of the price information originally used, although they said that 2002 prices were used.
